Resveratrol triggers anti-proliferative and apoptotic effects in FLT3-ITD-positive acute myeloid leukemia cells via inhibiting ceramide catabolism enzymes
- 20 January 2022
- journal article
- research article
- Published by Springer Nature in Medical Oncology
- Vol. 39 (3) , 1-13
Abstract
Resveratrol possesses well-defined anti-carcinogenic activities. However, how resveratrol exerts its anti-leukemic actions by modulating anti-apoptotic ceramide catabolism enzymes, mainly sphingosine kinase (SK-1) and glucosylceramide synthase (GCS), in FLT3-ITD AML remains unclear. Resveratrol, SKI II (SK inhibitor) and PDMP (GCS inhibitor) were evaluated alone or in combinations for their effect on cell proliferation (MTT assay), apoptosis (annexin V-FITC/PI staining by flow cytometry) and cell cycle progression (PI staining by flow cytometry) in MOLM-13 and MV4-11 cells. The combination indexes (CIs) were calculated based on cell proliferation data using CompuSyn software. Caspase-3 and PARP activation, changes in SK-1 and GCS levels by resveratrol alone or PARP cleavage in co-treatments were determined by western blot. Resveratrol and inhibitors alone inhibited cell proliferation in a dose- and time-dependent manner. Resveratrol downregulated SK-1 and GCS expression in both cell lines. It induced apoptosis by phosphatidylserine (PS) exposure together with caspase-3 and PARP cleavage and arrested the cell cycle slightly at the S phase. Co-administrations intensified resveratrol’s effect by inhibiting cell proliferation synergistically (A CI of < 1) or additively (A CI 1.0–1.1) and inducing apoptosis via PS relocalization and PARP cleavage. Resveratrol plus SKI II did not affect cell cycle progression significantly, however, resveratrol plus PDMP blocked cycle progression at G0/G1 and S phases for MOLM-13 cells and MV4-11 cells, respectively. Overall, resveratrol may inhibit FLT3-ITD AML cell proliferation by inhibiting ceramide catabolism and be evaluated as a chemopreventive after detailed analysis of the crosstalk between resveratrol and ceramide catabolism pathway.Keywords
Funding Information
- Abdullah Gul University Scientific Research Projects Coordination Unit (FAB-2016-66)
This publication has 38 references indexed in Scilit:
- Resveratrol selectively induces apoptosis in malignant cells with the JAK2V617F mutation by inhibiting the JAK2 pathwayMolecular Nutrition & Food Research, 2015
- Revisiting the sphingolipid rheostat: Evolving concepts in cancer therapyExperimental Cell Research, 2015
- Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemiaJournal of Hematology & Oncology, 2013
- Inhibition of Sphingolipid Metabolism Enhances Resveratrol Chemotherapy in Human Gastric Cancer CellsBiomolecules & Therapeutics, 2012
- Resveratrol dimers are novel sphingosine kinase 1 inhibitors and affect sphingosine kinase 1 expression and cancer cell growth and survivalBritish Journal of Pharmacology, 2012
- Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2ABlood, 2011
- Resveratrol Triggers Apoptosis Through Regulating Ceramide Metabolizing Genes in Human K562 Chronic Myeloid Leukemia CellsNutrition and Cancer, 2011
- The sphingosine kinase‐1 survival pathway is a molecular target for the tumor‐suppressive tea and wine polyphenols in prostate cancerThe FASEB Journal, 2010
- The roles of bioactive sphingolipids in resveratrol-induced apoptosis in HL60 acute myeloid leukemia cellsJournal of Cancer Research and Clinical Oncology, 2010
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay MethodCancer Research, 2010